STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announces that it presented promising data from its ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

This new agent, like the other DPP-4 inhibitors, has a mechanism of action that affects both pancreatic ß-cell survival as well as ß-cell secretory function. These medications do not incite ...

Phenylephrine is included in many cold and flu products, but a scientific panel last year found that it doesn't really do its ...

Patients with sarcoidosis treated with ACE inhibitors had greater mortality risk than those treated with angiotensin receptor blockers.

DelveInsight's ROS1 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...

US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

and BioVie’s Triolex (bezisterim), an inhibitor of inflammatory mediators, which has a Phase III trial planned in the US due to its neuroprotective potential. Palmer adds: “26% of the pipeline DMTs in ...

Mind Medicine’s share price has responded very strongly to Q3 update that contained very little new information. Read why I ...